Additional Information
Market: NASDAQ
Sector: Pharmaceuticals & Biotech
Latest Price: 6.12  (2.00% Ascending)
52-week High: 11.15
52-week Low: 1.48
Market Cap: 242.66M
1 year chart
1 day chart
Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.

Anthera halts VISTA-16 heart drug trial

12th Mar 2012, 7:47 am by Joyanta Acharjee
Anthera halts VISTA-16 heart drug trial

Anthera Pharmaceuticals (NASDAQ:ANTH) late Friday stopped a late-stage trial of its experimental drug to treat a heart disease due to lack of efficacy.

The company, which develops drugs to treat cardiovascular and autoimmune disorders, said it halted enrollment in the clinical trial, known as VISTA-16, following recommendation by the independent Data Safety Monitoring Board (DSMB).

The Hayward, California-based company was testing its drug, varespladib methyl, in patients suffering from a heart condition known as acute coronary syndrome, which includes symptoms such as chest pain caused by reduced blood flow to the heart.

In a statement, Anthera said: "Based on all the evidence we have seen regarding varespladib and secretory phospholipase, and in light of previous study results, we were surprised by the recommendation from the DSMB," the company in a statement.

Anthera's president and chief executive officer Paul F. Truex said: "While the DSMB information we received today was both surprising and disappointing, our focus is on the best interests of patients and making sure all this information is communicated to appropriate medical and regulatory authorities as quickly as possible."

The VISTA-16 trial was designed to prove the hypothesis that reduction of inflammation, particularly following an ACS, leads to improved outcomes in patients with cardiovascular disease.

The study compared a combination of varespladib, the cholesterol drug Lipitor, and other standard treatments to Lipitor, the standard treatment, and a placebo in patients who have acute coronary syndrome.

Currently, the best practice to slow coronary artery disease progression and reduce the risk of a subsequent heart attack is directed at the treatment of individual cardiovascular risk factors such as high cholesterol or clotting.

Anthera, which went public in March 2010, is currently testing two other drugs - for lupus and acute chest syndrome - in separate mid-stage trials.

No investment advice

Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here